Hormone Optimization and Health for Everyone

Integrative Hormone Optimization and Health: An Evidence-Based, Chiropractic-Informed Guide

Abstract

In this educational post, I walk you through a practical, research-informed approach to optimizing hormones in all individuals, addressing iron deficiency, cyclic progesterone for heavy bleeding, PCOS considerations, post–gastric bypass care, and the physiology of testosterone therapy. I also discuss contraception choices around age 40–45, SHBG-driven symptoms, and the nuanced use of progesterone versus progestins. Throughout, I highlight how integrative chiropractic care and functional medicine principles support endocrine regulation, inflammatory control, vascular safety, and musculoskeletal resilience. Clinical observations from my practice inform the protocols presented, and I link them to the latest evidence from leading researchers using modern, high-quality methods.

Iron Deficiency, Heavy Bleeding, and Cyclic Progesterone: Getting the Fundamentals Right

When I meet a woman with fatigue, heavy periods, or cognitive fog, I first consider iron metabolism and menstrual blood loss. Many women present with iron deficiency, even when hemoglobin appears acceptable, because ferritin and transferrin saturation better reflect true iron status. Chronic heavy bleeding depletes iron stores and precipitates anemia, impairs thyroid hormone utilization, and worsens fatigue and mood symptoms.

• Key points:
  • Assess ferritin, transferrin saturation, CBC, and reticulocyte count.
  • Replete iron with gentle protocols (e.g., oral ferrous bisglycinate or sucrosomial iron) to maximize absorption and minimize GI upset.
  • Coordinate thyroid evaluation: TSH, free T4, free T3, reverse T3, and thyroid antibodies for a complete picture.

Why cyclic progesterone? In women with heavy bleeding and luteal phase insufficiency, cyclic micronized progesterone can reduce endometrial proliferation, stabilize the lining, and decrease blood loss. The physiology is straightforward: progesterone opposes estrogen-driven endometrial growth, improves spiral artery regulation, and shortens the duration of bleeding. I often initiate cyclic micronized progesterone in the luteal phase while correcting iron and supporting thyroid function; the combination reduces bleeding and restores energy by addressing both input (blood loss) and systemic utilization (thyroid-driven metabolic rate) (Barbieri, 2020; ACOG, 2021).

• Practical approach:
  • Begin cyclic micronized progesterone in the luteal phase (e.g., days 14–28) and adjust based on cycle length and bleeding.
  • Pair with iron repletion and a thyroid-appropriate protocol to improve cellular oxygen delivery and metabolic efficiency.
  • Monitor ferritin target 50–100 ng/mL for symptom resolution while avoiding iron overload.

Section Title: PCOS, SHBG, and Progesterone Nuances: Tailoring to the Individual

Polycystic ovary syndrome (PCOS) involves hyperandrogenism, ovulatory dysfunction, and metabolic dysregulation. Elevated insulin increases variability in hepatic production of sex hormone–binding globulin (SHBG) and alters free androgen and estrogen availability. Women on combined oral contraceptives often show very high SHBG values; this binds circulating testosterone with little increase in free T, leaving them symptomatic despite normal or high total values (Escobar-Morreale, 2018; ACOG, 2019).

• Clinical reasoning:
  • If a 45-year-old patient has very high SHBG (e.g., 115 nmol/L) and significant symptoms, her free testosterone may remain low until total values are quite high; many clinicians hesitate to titrate to effective total levels.
  • Consider contraception alternatives that reduce SHBG impact, such as a levonorgestrel intrauterine device (IUD), thereby improving free hormone availability and symptom response.
  • Treat PCOS with insulin-sensitizing strategies (nutrition, physical activity, inositol, metformin, if appropriate) alongside cyclic progesterone to support regularity and reduce the risk of endometrial hyperplasia.

Why this matters: By shifting contraception to an option that does not drive SHBG upward, we reduce binding of bioactive hormones and restore physiologic signaling. Cyclic progesterone addresses heavy bleeding and PMS symptoms without the thrombotic risks associated with estrogen-containing pills in older age groups (Legro et al., 2013; ACOG, 2019).

Post–Gastric Bypass Care: Absorption, Microbiome, and Targeted Supplementation

Bariatric procedures alter gastric acidity, transit time, and absorptive surface area. Patients are at greater risk of deficiencies in iron, B12, folate, fat-soluble vitamins, and trace minerals. Because nutrient absorption shifts distally, we must rethink dosing forms and microbiome support (ASMBS, 2020).

• Practical steps:
  • Use more bioavailable nutrient forms (e.g., methylcobalamin sublingual, transdermal Vitamin D3/K2 when needed, chelated minerals).
  • Employ probiotics and prebiotics to support lower bowel reconditioning and SCFA production; consider multi-strain formulations with Lactobacillus and Bifidobacterium species.
  • Monitor iron, ferritin, B12, folate, Vitamin D, zinc, copper, and thiamine regularly.

Physiology: Lower gastric acidity decreases iron and B12 liberation from food, while altered transit reduces contact with absorptive sites. Microbiome shifts can modulate estrogen recycling via the estrobolome, affecting hormone balance and systemic inflammation. Supporting the gut improves nutrient uptake and endocrine homeostasis (Wilson et al., 2020).

Testosterone Therapy Physiology: Absorption, Distribution, and Renal Excretion

Understanding testosterone kinetics guides safer dosing and better outcomes. Transdermal or pellet-based testosterone follows an intuitive pharmacokinetic path:

• Absorption: Dependent on skin surface area, capillary perfusion, and cardiac output. Increased physical activity improves perfusion, enhancing absorption from pellets or creams.
• Distribution: Influenced by body mass and composition. After significant weight loss, there is less tissue volume to distribute the dose, often resulting in a stronger clinical response to the same dose. Conversely, higher BMI dilutes concentration across larger compartments.
• Excretion: Primarily renal. Older adults with reduced renal clearance maintain higher levels for longer; hence, lower doses can last for months.

In my practice, older men may maintain therapeutic pellet levels for 6–9 months due to slower excretion. In younger, active patients, pellets are metabolized more quickly, necessitating standard durations of 3–4 months. Thinking in terms of absorption, distribution, and excretion allows us to set expectations and adjust dose and interval appropriately (Bhasin et al., 2018).

• Managing estrogenic symptoms:
  • Early therapy sometimes triggers transient breast tenderness due to rapid shifts in aromatization and receptor sensitivity. This typically resolves once steady state is achieved.
  • In men with persistent symptoms, lifestyle measures (weight loss, reduced alcohol, sleep optimization) lower aromatase activity. Selective use of nutraceuticals such as diindolylmethane (DIM) may aid estrogen metabolism, but I reserve anti-estrogen drugs for specific, documented indications, ensuring we do not blunt anabolic benefits without cause (Eisenberg et al., 2017).

DVT Risk, Contraception After Age 40, and Safer Symptom Control

Deep vein thrombosis risk rises with estrogen-containing contraceptives, especially as age and vascular risk factors accumulate. For a woman around age 45 who no longer needs pregnancy prevention (IUD or tubal ligation already in place), continuing combined pills for period control is rarely a favorable risk–benefit decision. Instead, I address heavy bleeding and PMS with non-estrogen options: cyclic micronized progesterone, levonorgestrel IUD, or targeted endometrial therapy depending on the case (ACOG, 2019; Lidegaard et al., 2012).

• Strategy:
  • Clarify the purpose of contraception: pregnancy prevention vs symptom management.
  • If pregnancy prevention is covered, discontinue estrogen pills and transition to a progestin IUD or cyclic progesterone for bleeding/PMS.
  • Evaluate SHBG, free and total testosterone, thyroid, and replete iron when bleeding has been heavy.
  • This reduces thrombotic risk while effectively addressing symptoms.

Progesterone vs Progestins: Different Molecules, Different Outcomes

It is essential to differentiate natural micronized progesterone from synthetic progestins (e.g., medroxyprogesterone acetate, norethindrone). Micronized progesterone binds progesterone receptors with physiologic signaling, supports sleep and mood through GABAergic effects, and has a more favorable metabolic and vascular profile. Progestins are designed for contraception; they can activate androgenic, glucocorticoid, and mineralocorticoid pathways to varying degrees, with different effects on lipids, insulin sensitivity, and breast tissue (Stute et al., 2016; Santen et al., 2020).

• Clinical implications:
  • In perimenopause and menopause, micronized progesterone is often preferred for symptom control, sleep quality, and endometrial protection alongside transdermal estradiol when indicated.
  • In premenopausal contraception, progestins are used for pregnancy prevention; they are not interchangeable with progesterone when the main goal is symptom relief.
  • For heavy bleeding without contraception needs, micronized progesterone cyclic regimens can be safer and more effective.

Environmental Factors, SHBG Modulation, and Realistic Expectations

Patients frequently ask about environmental exposures and supplements that claim to lower SHBG. While certain nutrients and lifestyle strategies can shift SHBG by 10–15%, this modest change often does not translate into clinically meaningful differences in free hormone levels for symptomatic patients. I focus on targeted endocrine drivers: insulin resistance, thyroid status, iron deficiency, hepatic health, and inflammation. A realistic conversation prevents frustration and directs effort to interventions with measurable impact (Dunn et al., 2015).

Integrative Chiropractic Care: Bridging Neuroendocrine, Vascular, and Musculoskeletal Health

Integrative chiropractic care complements hormone optimization by improving autonomic balance, reducing mechanical pain generators, and enhancing circulation and lymphatic flow. The neurophysiological rationale includes:

• Autonomic regulation: High sympathetic tone exacerbates vasoconstriction, sleep disruption, and cortisol dysregulation. Gentle spinal manipulation, myofascial release, and breathing techniques reduce sympathetic dominance and improve vagal tone, supporting uniformity of hormonal rhythms and menstrual regularity.
• Pain and inflammation: Mechanical pain amplifies systemic cytokine levels (IL-6, TNF-α), which can interfere with gonadal hormone signaling and thyroid hormone conversion. Addressing sacroiliac dysfunction, thoracolumbar junction restrictions, and cervical proprioception reduces inflammatory load, improving endocrine responsiveness.
• Circulation and lymphatics: Mobilization and targeted exercise prescriptions increase the efficacy of the muscular pump, aiding venous return and mitigating edema—particularly relevant when managing heavy bleeding, fatigue, or estrogen-related fluid changes.

In my clinical observations at the Sciatica & Chiropractic Clinic and across my patient cohort, combining endocrine protocols with chiropractic-informed movement retraining yields better sleep, fewer PMS symptoms, and a more stable mood. I also employ functional nutrition and gut-focused care to support the estrobolome and metabolic flexibility, particularly in patients with PCOS and post–gastric bypass.

• Integrative plan components:
  • Spine and pelvis alignment to reduce nociceptive input and autonomic stress.
  • Prescribed walking intervals and resistance training to lower aromatase activity and improve insulin sensitivity.
  • Diaphragmatic breathing, HRV biofeedback, and sleep hygiene to stabilize cortisol and melatonin rhythms.
  • Gut-directed therapies (probiotics, fiber diversity, polyphenols) to balance estrogen metabolism.

Practical Dosing Nuances, Safety, and Patient Expectations

Patients sometimes request extra testosterone doses due to anecdotes from peers. I counsel that supraphysiologic dosing can lead to paradoxical outcomes: erectile softness due to receptor downregulation or increased aromatization, fluid shifts, and mood volatility. Evidence-based dosing respects physiological windows while monitoring hematocrit, lipids, liver enzymes, and PSA in men. For women, I titrate carefully to avoid virilizing effects and balance symptom relief with safety (Bhasin et al., 2018).

• Safeguards:
  • Check hematocrit/hemoglobin thresholds and avoid unnecessary elevations; manage with dose adjustment and lifestyle before considering phlebotomy.
  • Track SHBG, free testosterone (calculated or measured via equilibrium dialysis), estradiol, and progesterone.
  • In older adults, adjust for slower renal excretion to prevent prolonged supra-therapeutic levels.

Case-Inflected Insights: Weight Loss, Testosterone, and Dose Response

Significant weight loss reduces distribution volume, often increasing effective testosterone exposure per unit dose. I have observed that patients who drop 20% of body fat achieve target symptom resolution with lower or less frequent dosing, while those with persistent central adiposity may need more aggressive lifestyle intervention to reach the same endpoints. In women, I am cautious with testosterone; we use the lowest dose necessary for sexual function, energy, or musculoskeletal support, and we reassess frequently to maintain a favorable safety profile (Eisenberg et al., 2017).

Clinical Workflow: Building the Right Team and Sequence

Complex endocrine cases benefit from a coordinated care team: primary care, endocrinology or women’s health, nutrition, and integrative chiropractic. My workflow emphasizes:

• Initial labs: CBC, ferritin, transferrin saturation, TSH, free T4/T3, insulin, fasting glucose, HOMA-IR, SHBG, total and free testosterone, estradiol, progesterone, hs-CRP, and Vitamin D.
• Prioritize bleeding control and iron repletion before escalating hormone therapies.
• Choose a contraception aligned with vascular safety and symptom goals.
• Integrate movement and stress modulation early to improve absorption and clearance dynamics.

This sequence reduces risk, clarifies clinical signals, and preserves patient trust through predictable milestones.

Key Takeaways and Next Steps

• Correct iron deficiency and stabilize thyroid function before refining hormone dosing; both are foundational to energy and mood.
• Use cyclic micronized progesterone to reduce heavy bleeding; reserve estrogen-containing pills in older patients only when pregnancy prevention is necessary, and risks are acceptable.
• In PCOS, prioritize insulin sensitization, weight management, and low-SHBG-impact contraception to enhance free hormone bioavailability.
• Understand testosterone kinetics (absorption, distribution, and excretion) to set dosing intervals; older adults often require lower doses with longer durations due to reduced clearance.
• Leverage integrative chiropractic care to modulate autonomic tone, reduce inflammation, and support musculoskeletal resilience; improved physiology amplifies endocrine therapy effectiveness.

---

References

• ACOG Practice Bulletin: Management of Abnormal Uterine Bleeding (American College of Obstetricians and Gynecologists, 2021).
• ACOG Committee Opinion on Polycystic Ovary Syndrome (American College of Obstetricians and Gynecologists, 2019).
• ASMBS Nutritional Guidelines for the Surgical Weight Loss Patient (American Society for Metabolic and Bariatric Surgery, 2020).
• Testosterone Therapy in Men: Endocrine Society Clinical Practice Guideline (Bhasin, S., et al., 2018).
• Male Reproductive Endocrinology and Fertility Outcomes with Testosterone (Eisenberg, M. L., et al., 2017).
• Estrobolome and Gut Microbiota in Hormone Metabolism (Wilson, A. S., et al., 2020).
• SHBG and Metabolic Health in Women (Dunn, J. F., et al., 2015).
• PCOS: From Pathophysiology to Therapy (Escobar-Morreale, H. F., 2018).
• Hormone Therapy and Thrombosis Risk in Women (Lidegaard, Ø., et al., 2012).
• Micronized Progesterone vs Progestins: Vascular and Metabolic Considerations (Stute, P., et al., 2016).
• Menopausal Hormone Therapy: Evidence and Safety (Santen, R. J., et al., 2020).
• Gynecologic Endocrinology: Mechanisms and Clinical Applications (Barbieri, R. L., 2020).